The conformational requirements of suramin for its binding to basic fibroblast growth factor
(bFGF) and platelet-derived growth factor (PDGF) were examined by molecular modeling …

The design, synthesis, and biological evaluation of a series of pyrrole and pyrazole
congeners 2 of suramin, directed toward the development and identification of new ligands …

Recent data show that anti-angiogenesis may provide a promising route to treat cancer.
Fibroblast growth factors (FGFs) are powerful angiogenic polypeptides, whose mitogenic …

Fibroblast growth factors (FGFs) play crucial roles in the regulation of key cellular processes
such as angiogenesis, differentiation, and tumor growth. Suramin, a polysulfonated …

Some heterocyclic analogs of suramin with potent and selective basic fibroblast growth
factor (bFGF) complexing activity have been synthesized. The possible mode of action of …

Suramin, an anticancer agent in current clinical trials, is a prototype of a pharmacological
antagonist of growth factors, including basic fibroblast growth factor (bFGF). Suramin …

This research work focuses on the determination for the first time of the 3D solution structure
of potent anticancer drug suramin, investigation of its conformational properties, and use of …

Vascular Endothelial Growth Factor (VEGF) is a specific endothelial mitogen and an
important angiogenic factorin vivo, capable of inducing therapeutic angiogenesis when …

Revised Manuscript Received July 6, 1992 abstract: Suramin inhibits the binding of a variety
of growth factors to their cell surface receptors. The direct interaction of suramin with acidic …

Angiogenesis inhibitors are currently in clinical development for cancer. These agents pose
unique developmental challenges:(a) determining maximum biological doses versus …